The Academy has released its revised policy statement, Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients (published online at www.aap.org/advocacy/releases/mengpolicyfinal.pdf).

The policy recommends administration of quadravalent meningococcal conjugate vaccine (MCV4, Menactra) to young adolescents at the 11- to 12-year visit, students entering high school or 15 year-olds (whichever comes first),and college freshmen who will be living in dormitories. MCV4 also is recommended for pediatric patients 11 years and older who are at increased risk of meningococcal disease (e.g., adolescents with asplenia or with complement deficiencies).

While the statement says MCV4 is preferred, use of the meningococcal polysaccharide vaccine (MPSV4, Menomune) is acceptable for certain adolescents at high risk (e.g., travelers to hyperendemic regions or for control of outbreaks).

Menactra, manufactured by sanofi pasteur, was licensed in January 2005 for use in 11 - to 55-year-olds to protect against invasive meningococcal disease(IMD) caused...

You do not currently have access to this content.